Dr. Liang Zhang

Dr. Liang Zhang Dr. Liang Zhang
Mayo Clinic, Rochester, MN USA
Dr. Zhang received her B.S. from Kansas State University and her Ph.D. in Pharmacology and Toxicology in University of Kansas. She was a Postdoctoral Fellow (2012-2015) at Mayo Clinic Rochester, MN where she identified novel therapeutic target in mitochondria that promote alternative treatment strategies against Alzheimer?s disease. Dr. Zhang?s researches focused on identify novel therapeutic targets, study mechanism of action of drug and cellular bioenergetics. Dr. Zhang currently works in the Department of Neurological Surgery at Mayo Clinic, Rochester where she identifies therapeutic vulnerabilities and metabolic anomaly in Diffuse Intrinsic Pontine Glioma (DIPG). This tumor occurs primarily in children and currently has no cure.
Research Interest
?Study the molecular mechanism(s) of pediatric brain tumor specifically focused on diffuse pontine intrinsic glioma (DIPG). ?Identify FDA-approved drug that has efficacy for DIPG ?Study metabolomic changes of glutamine metabolism in DIPG ?Study the molecular mechanism(s) of mitochondrial dysfunction in Alzheimer?s disease ?Identify mitochondria-based drug development for Alzheimer?s disease ?Identify biomarkers using metabolomics in Alzheimer?s disease ?Animal colonies manager ?Identified key drug mechanism of a C-terminus 90 kDa heat shock protein (Hsp90) modulator as therapeutic intervention for diabetic neuropathy ?Developed a primary neuron-based high-throughput drug assay screening for of C-terminal HSP90 modulators ?Quantitatively analyze global changes in models of diabetic neuropathy using stable isotope labeling with amino acids in cell culture (SILAC) ?Screened micro-RNA targets in Streptozotocin (STZ)-induced Type-I diabetic mice. ?Validated functionality of USMG5, a novel protein target identified from proteomic studies, as part of the regulatory unit of ATP synthase. ?Study raft-like liposomes synthesis and targeted-peptide delivery into cancer sites. ?Recipient of K-INBRE (Kansas IDeA Network of Biomedical Research Excellence) scholarship ?Synthesis of a class of tricyclic pyrones and analogs that targeted at disaggregating the amyloid beta 1?42 (A? 1?42). ?Studied the in vitro interaction of tricyclic pyrones and their analogs with A?42.